Samsara BioCapital
Overview
Investment advisory for biotech innovation and company development.
Founded
2016
Deals ยท 12mo
13
Stage focus
Geographic focus
Sector focus
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
R1 Therapeutics | Sep 2026Participated | $3 MSeries A | |
Link Cell Therapies | Sep 2026Participated | $30 MSeries A | |
Abcuro | Aug 2026Participated | $66 MSeries D | |
Claris Biotherapeutics | Jul 2026Led | $118 MSeries B | |
Nura Bio | Jun 2026Participated | $74 MSeries B | |
Coultreon Biopharma | Apr 2026Participated | $125 MSeries A | |
Sidewinder Therapeutics | Apr 2026Participated | $137 MSeries B | |
Ambrosia Biosciences | Mar 2026Participated | $100 MSeries B | |
Primmune Therapeutics | Jan 2026Participated | $9 MSeries B | |
EpiBiologics | Jan 2026Participated | $107 MSeries B | |
PsiThera | Dec 2025Led | $48 MSeries A | |
Excellergy | Dec 2025Led | $70 MSeries A | |
R1 Therapeutics | Sep 2026Participated | $3 MSeries A | |
Link Cell Therapies | Sep 2026Participated | $30 MSeries A | |
Abcuro | Aug 2026Participated | $66 MSeries D | |
Claris Biotherapeutics | Jul 2026Led | $118 MSeries B | |
Nura Bio | Jun 2026Participated | $74 MSeries B | |
Coultreon Biopharma | Apr 2026Participated | $125 MSeries A | |
Sidewinder Therapeutics | Apr 2026Participated | $137 MSeries B | |
Ambrosia Biosciences | Mar 2026Participated | $100 MSeries B | |
Primmune Therapeutics | Jan 2026Participated | $9 MSeries B | |
EpiBiologics | Jan 2026Participated | $107 MSeries B | |
PsiThera | Dec 2025Led | $48 MSeries A | |
Excellergy | Dec 2025Led | $70 MSeries A |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 0 | 1 |
| Series A | 6 | 30 |
| Series B | 8 | 39 |
| Series C+ | 4 | 26 |
| Other Equity | 0 | 7 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Dec '17 | 1 |
| Jan '18 | 0 |
| Feb '18 | 0 |
| Mar '18 | 0 |
| Apr '18 | 0 |
| May '18 | 0 |
| Jun '18 | 0 |
| Jul '18 | 1 |
| Aug '18 | 0 |
| Sep '18 | 1 |
| Oct '18 | 1 |
| Nov '18 | 0 |
| Dec '18 | 0 |
| Jan '19 | 1 |
| Feb '19 | 2 |
| Mar '19 | 0 |
| Apr '19 | 1 |
| May '19 | 2 |
| Jun '19 | 0 |
| Jul '19 | 0 |
| Aug '19 | 1 |
| Sep '19 | 1 |
| Oct '19 | 0 |
| Nov '19 | 1 |
| Dec '19 | 1 |
| Jan '20 | 0 |
| Feb '20 | 0 |
| Mar '20 | 1 |
| Apr '20 | 0 |
| May '20 | 1 |
| Jun '20 | 1 |
| Jul '20 | 3 |
| Aug '20 | 1 |
| Sep '20 | 8 |
| Oct '20 | 4 |
| Nov '20 | 2 |
| Dec '20 | 2 |
| Jan '21 | 4 |
| Feb '21 | 3 |
| Mar '21 | 2 |
| Apr '21 | 3 |
| May '21 | 2 |
| Jun '21 | 3 |
| Jul '21 | 1 |
| Aug '21 | 2 |
| Sep '21 | 4 |
| Oct '21 | 2 |
| Nov '21 | 1 |
| Dec '21 | 0 |
| Jan '22 | 2 |
| Feb '22 | 3 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 4 |
| Jul '22 | 1 |
| Aug '22 | 0 |
| Sep '22 | 2 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 2 |
| Jan '23 | 1 |
| Feb '23 | 0 |
| Mar '23 | 1 |
| Apr '23 | 0 |
| May '23 | 2 |
| Jun '23 | 1 |
| Jul '23 | 2 |
| Aug '23 | 1 |
| Sep '23 | 1 |
| Oct '23 | 0 |
| Nov '23 | 2 |
| Dec '23 | 1 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 2 |
| Apr '24 | 3 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 1 |
| Aug '24 | 1 |
| Sep '24 | 3 |
| Oct '24 | 2 |
| Nov '24 | 0 |
| Dec '24 | 1 |
| Jan '25 | 2 |
| Feb '25 | 1 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 1 |
| Jun '25 | 1 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 3 |
| Jan '26 | 2 |
| Feb '26 | 0 |
| Mar '26 | 1 |
| Apr '26 | 2 |
| May '26 | 0 |
| Jun '26 | 1 |
| Jul '26 | 1 |
| Aug '26 | 1 |
| Sep '26 | 2 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 120 |
| Space & Frontier Tech | 4 |
| AI & Machine Learning | 3 |
| Consumer & Lifestyle | 3 |
| Professional Services | 2 |
| Networks, Cloud & Communication | 1 |
| Fintech | 1 |
| Data, Analytics & IT | 1 |
| Developer Tools | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 1 |
| $5M-$10M | 1 |
| $10M-$25M | 3 |
| $25M-$50M | 14 |
| $50M-$100M | 42 |
| $100M-$250M | 54 |
| $250M-$500M | 6 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 5 of 5 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 108 |
| Europe | 7 |
| Canada | 4 |
| China | 1 |
| V5t 1m4 | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| RA Capital Management | 24 |
| Janus Henderson Investors | 20 |
| OrbiMed | 20 |
| BVF Partners | 19 |
| Cormorant Asset Management | 17 |
| Redmile Group | 17 |
| Surveyor Capital | 17 |
| Logos Capital | 16 |
| EcoR1 Capital | 15 |
| Invus | 14 |
| Casdin Capital | 13 |
| Rock Springs Capital | 12 |
| venBio Partners | 11 |
| Alexandria Venture Investments | 10 |
| Versant Ventures | 10 |
| Boxer Capital | 9 |
| Foresite Capital | 9 |
| HBM Healthcare Investments | 9 |
| Perceptive Advisors | 9 |
| The Column Group | 9 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 18 | 15% |
| Participating | 103 | 85% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 5 | 28% |
| Co-led | 13 | 72% |
Team
Principal
Head of Public Research
Venture Partner
Partner
Entrepreneur Partner
Founder & Managing Partner
Venture Partner